Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study

Figure 2

Subgroup analysis of the mean eGFR difference of the patients with baseline eGFR <60 mL/min/1.73 m² (a) and ≥60 mL/min/1.73 m² (b) who received SGLT2i and DPP4i for 3, 6, 9, 12, 15, and 18 months. The error bars represent a 95% confidence interval.

(a)

(b)